Biotech RadarJobs updated

COMPANY

Arcturus Therapeutics

arcturusrx.com ↗ · West Coast

Clinical Phase 3

2 open jobs · last seen Oct 23, 2026 · 14 sources

Arcturus Therapeutics develops mRNA medicines, including an mRNA replacement therapy that delivers CFTR mRNA to the airways of cystic fibrosis patients and an mRNA medicine for OTC deficiency. From company website Source · Oct 12, 2026

Keywords: mRNA Ornithine Transcarbamylase Deficiency Human Influenza COVID-19 Corona Virus Infection OTC Deficiency SARS-CoV-2 CFTR Gene Mutation SARS-CoV-2 Infection Covid19 SARS-CoV Infection ARCT-810 ARCT-032 ARCT-021 ARCT-2304 ARCT-2303 ARCT-165 ARCT-154 ARCT-2138

Profile checked Oct 10, 2026

2Open jobs13Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Research Assistant / Research Associate I, Molecular BiologySan Diego, CA, USSep 1, 2026Oct 16, 2026
Director, Head of Drug DiscoverySan Diego, CA, USJul 14, 2026Oct 16, 2026

See all 2 jobs

Timeline

  1. Partnership Partnership / licensing announced Jul 2, 2026. Source: SEC filing. source ↗
  2. Trial start Phase 2: Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis source ↗
  3. Trial start Phase 1/Phase 2: Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults source ↗
  4. Trial start Phase 2: A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD source ↗
  5. Trial start Phase 3: Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults source ↗
  6. Trial start Phase 1: Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults source ↗
  7. Trial start Phase 1: Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis. source ↗
  8. Trial start Phase 2: Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810 source ↗
  9. Trial start Phase 1/Phase 2: A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults source ↗
  10. Trial start Phase 2: A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults source ↗
  11. Trial start Phase 2: Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021 source ↗
  12. Trial start 1: Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency source ↗
  13. Trial start Phase 1/Phase 2: Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects source ↗
  14. Trial start Phase 1: Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Clinical trials (lead sponsor) 13

RecordTitlePhaseStatusStartPrimary completion
NCT06602531Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in AdultsPhase 1/Phase 2CompletedDec 10, 2024Jun 13, 2025 (actual)
NCT06747858Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic FibrosisPhase 2RecruitingDec 12, 20242027-06 (estimated)
NCT06279871Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in AdultsPhase 3CompletedMar 27, 2024Oct 9, 2024 (actual)
NCT05037097A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy AdultsPhase 1/Phase 2CompletedAug 30, 2021Dec 19, 2023 (actual)
NCT06125691Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in AdultsPhase 1CompletedJan 22, 2024Aug 10, 2024 (actual)
NCT05526066Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810Phase 2TerminatedOct 17, 2022Oct 31, 2024 (actual)
NCT04668339A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy AdultsPhase 2TerminatedJan 7, 2021Mar 1, 2022 (actual)
NCT06488313A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCDPhase 2RecruitingNov 4, 2024Jun 1, 2026 (estimated)
NCT04728347Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021Phase 2TerminatedJan 4, 2021Dec 28, 2021 (actual)
NCT05712538Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.Phase 1CompletedFeb 15, 2023Jul 29, 2024 (actual)
NCT04442347Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency1CompletedNov 3, 2020Aug 30, 2023 (actual)
NCT04416126Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult SubjectsPhase 1CompletedJun 1, 2020Dec 9, 2020 (actual)
NCT04480957Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult SubjectsPhase 1/Phase 2CompletedAug 4, 2020Jan 29, 2021 (actual)

Open jobs 2

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Research Assistant / Research Associate I, Molecular BiologySan Diego, CA, USSep 1, 2026Oct 16, 2026Entry
Director, Head of Drug DiscoverySan Diego, CA, USJul 14, 2026Oct 16, 2026Executive

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Feedback